LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which was recently shipped from Europe, has cleared customs in the United States.
OKYO is now in the process of having randomization codes generated for its double blinded placebo-controlled trial, along with other activities needed for initiating the trial, including authorization of those clinical sites planned for the Phase 2 clinical trial. Once these activities are completed, the drug for the study is planned to be shipped to those sites involved in the trial. OKYO is anticipating the first-patient-first visit in Q1 2023 and looking to release top-line data from this trial in Q4 2023.
“Initiation of the first-in-human Phase 2 trial for OK-101 to treat DED has been a central and critical goal for the company for the past 18 months,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma Ltd. “We are excited to be very close now to moving this drug into clinical trials and believe that OK-101 can provide a new way to treat DED patients who are presently not well-served by currently approved drugs.”
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 has been shown to produce anti-inflammatory and neuropathic pain-reducing activities in mouse models of DED and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the drug molecule to enhance the residence time of OK-101 within the ocular environment.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further information, please visit the Company's website at www.okyopharma.com
The person who arranged for the release of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.
Gary S. Jacob, Chief Executive Officer
The EV upstart, seen as a serious rival to Tesla, plans to raise additional capital to finance its operations. The stock falls.
There are few things investors enjoy more than receiving a dividend payment each quarter. However, a popular ETF from JPMorgan, the JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), takes this approach and does it one better by paying investors a dividend on a monthly basis. Not only that, but JEPI’s dividend yield is a massive 11.8% on a trailing basis, which is more than seven times the average yield for the S&P 500 of 1.65% and nearly three times the yield that investors can get from 10-yea
In 2022, Cathie Wood and Ken Griffin’s paths couldn’t have diverged any more sharply. While Wood’s bet on innovative growth-flavored stocks proved disastrous with her flagship ARKK fund posting huge losses, Griffin’s Citadel hedge fund notched profits of $16 billion – the most Wall Street had ever seen. But while the two famous investors’ fortunes differed dramatically last year, the pair have some things in common; both try to beat the market using singular techniques whether it’s Wood’s pencha
The purchases, which occurred on Friday, Monday and Tuesday (today), were made at prices ranging from about $59 to $62 a share and are Berkshire’s first purchases since the end of the third quarter. Berkshire also owns around $27 billion in Chevron stock (ticker: CVX). Berkshire Hathaway (BRK/A, BRK/B) now holds a roughly 22.1% stake in Occidental Petroleum (OXY), whose shares were down 1.4% Tuesday to $60.85.
Inflation remains high, and that was on the mind of Jerome Powell as the Federal Reserve chair gave testimony to the Senate Banking committee today. Powell made it clear that the central bank is likely to lift interest rates higher than previously anticipated. Currently, the Fed’s key funds rate is set in the range of 4.5% to 4.75%. “Although inflation has been moderating in recent months, the process of getting inflation back to 2% has a long way to go, and is likely to be bumpy… The latest eco
While 2023 is still relatively young, the markets have already proved to be extremely difficult to navigate this year. Bullish in January, bearish in February and back to the bull again so far in March, the swings make it impossible to know what’s up next. One simple solution to help make sense of the confusion is to just take a leaf out of the “legendary investor” playbook. And hardly any come more legendary than George Soros. Some quarters might not be too keen on the “man who broke the bank o
The firm's analysts give them all wide moats, meaning they will have competitive advantages for at least 20 years.
Shares of branding and marketing company Troika Media Group Inc. fell 51% after hours to 28 cents, following a 27% decline in the regular session after it reported financial results.
Fed chief Jerome Powell signaled rate hikes will go higher and faster than previously expected. The major indexes fell sharply.
The average brokerage recommendation (ABR) for NIO Inc. (NIO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
The company late on Friday said that effective immediately it made a "risk-based decision" to discontinue the Silvergate Exchange Network, which enabled round-the-clock transfers between investors and crypto exchanges, unlike traditional bank wires, which can often take days to settle. U.S. regulators have been sent to the headquarters of Silvergate as the company looks for a way to stay in business, the report said. One possible option involves lining up crypto-industry investors to help Silvergate shore up its liquidity, the report said.
With Apple leading the pack and other tech firms following, these are the 10 most profitable companies in the world by 12-month trailing net income.
GE's stock is too richly valued, warns the influential JPM coverage team.
The Federal Reserve will likely need to raise interest rates more than expected in response to recent strong data and is prepared to move in larger steps if the "totality" of incoming information suggests tougher measures are needed to control inflation, Fed Chair Jerome Powell told U.S. lawmakers on Tuesday. "The latest economic data have come in stronger than expected, which suggests that the ultimate level of interest rates is likely to be higher than previously anticipated," Powell said in prepared remarks for a hearing before the Senate Banking Committee. U.S. stocks sold off, Treasury yields rose and the dollar extended a gain after Powell's comments, his first since inflation unexpectedly jumped in January and the U.S. government reported an unusually large increase in payroll jobs for that month.
CrowdStrike reported Q4 profit and sales that topped estimates while revenue guidance came in well above Wall Street targets.
CEO Sundar Pichai is cutting back on large pay rises, as investors demand management take more forceful action to reduce its bloated cost base.
The U.S. Federal Reserve could raise interest rates to 6% and keep them there for an extended period of time to fight inflation, said Rick Rieder, chief investment officer of global fixed income at BlackRock, the world’s largest asset manager. Federal Reserve Chair Jerome Powell told U.S. lawmakers on Tuesday that the U.S. central bank could become more aggressive in its rate hike path following recent strong economic data.
Arguments in a closely-followed lawsuit between crypto firm Grayscale and the SEC suggested some investors are optimistic Grayscale's Bitcoin Trust could win approval to convert to an ETF.
Rivian shares are sliding today as the EV-maker announces plans for a “green” debt offering. Rivian says it intends to sell $1.3 billion worth of “green” convertible senior notes due in 2029, with the option to grant an additional $200 million worth of convertible notes to the original purchasers.
(Bloomberg) -- US banks are being forced to do something they haven’t done for 15 years: fight for deposits.Most Read from BloombergHolding Cash Will Be a Winning Strategy in 2023, Investors SayTrump’s Threat of a Third-Party Run Is Undercut by ‘Sore Loser’ LawsUS Banks Are Finally Being Forced to Raise Rates on DepositsTesla Slashes Model S and X Prices for the Second Time This YearTesla’s China Price War Sparks $18 Billion BYD Rout: Tech WatchAfter years of earning next to nothing, depositors